Stimulatory effect of growth hormone–releasing hormone (GHRH(1-29)NH2) on the proliferation, VEGF and chromogranin A secretion by human neuroendocrine tumor cell line NCI-H727 in vitro

Neuropeptides ◽  
2009 ◽  
Vol 43 (5) ◽  
pp. 397-400 ◽  
Author(s):  
Tomasz Stępień ◽  
Małgorzata Sacewicz ◽  
Hanna Ławnicka ◽  
Roman Krupiński ◽  
Jan Komorowski ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Tumor Cell ◽  
Neuroendocrine Tumor ◽  
Cell Line ◽  
Chromogranin A ◽  
Tumor Cell Line ◽  
Growth Hormone Releasing Hormone ◽  
Releasing Hormone

Ectopic Acromegaly Due to a Pancreatic Neuroendocrine Tumor Producing Growth Hormone-Releasing Hormone

2011 ◽  
Vol 17 (1) ◽  
pp. 79-84 ◽  
Author(s):  
Danielle Weiss ◽  
Hannes Vogel ◽  
M. Lopes ◽  
Steven Chang ◽  
Laurence Katznelson
Keyword(s):  
Growth Hormone ◽  
Neuroendocrine Tumor ◽  
Pancreatic Neuroendocrine Tumor ◽  
Growth Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Ectopic Acromegaly

Differential Secretion of Chicken Growth Hormone Variants After Growth Hormone-Releasing Hormone Stimulation In Vitro

Endocrine ◽  
2002 ◽  
Vol 17 (2) ◽  
pp. 91-102 ◽  
Author(s):  
Hilda Martínez-Coria ◽  
L Javier López-Rosales ◽  
Martha Carranza ◽  
Laura Berumen ◽  
Maricela Luna ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Growth Hormone Releasing Hormone ◽  
Releasing Hormone ◽  
Hormone Stimulation

The growth hormone–releasing hormone (GHRH) antagonist JV-1-36 inhibits proliferation and survival of human ectopic endometriotic stromal cells (ESCs) and the T HESC cell line

2010 ◽  
Vol 94 (3) ◽  
pp. 841-849 ◽  
Author(s):  
Marta Annunziata ◽  
Cristina Grande ◽  
Francesca Scarlatti ◽  
Francesco Deltetto ◽  
Elena Delpiano ◽  
...  
Keyword(s):  
Growth Hormone ◽  
Cell Line ◽  
Stromal Cells ◽  
Growth Hormone Releasing Hormone ◽  
Releasing Hormone

scholarly journals Matching anticancer compounds and tumor cell lines by neural networks with ranking loss

2022 ◽  
Vol 4 (1) ◽  
Author(s):  
Paul Prasse ◽  
Pascal Iversen ◽  
Matthias Lienhard ◽  
Kristina Thedinga ◽  
Chris Bauer ◽  
...  
Keyword(s):  
Tumor Cell ◽  
Cell Line ◽  
Cancer Cell ◽  
Drug Sensitivity ◽  
Inhibitory Concentration ◽  
Cancer Cell Line ◽  
Tumor Cell Line ◽  
Ranking Problem ◽  
Ranking Loss

ABSTRACT Computational drug sensitivity models have the potential to improve therapeutic outcomes by identifying targeted drug components that are likely to achieve the highest efficacy for a cancer cell line at hand at a therapeutic dose. State of the art drug sensitivity models use regression techniques to predict the inhibitory concentration of a drug for a tumor cell line. This regression objective is not directly aligned with either of these principal goals of drug sensitivity models: We argue that drug sensitivity modeling should be seen as a ranking problem with an optimization criterion that quantifies a drug’s inhibitory capacity for the cancer cell line at hand relative to its toxicity for healthy cells. We derive an extension to the well-established drug sensitivity regression model PaccMann that employs a ranking loss and focuses on the ratio of inhibitory concentration and therapeutic dosage range. We find that the ranking extension significantly enhances the model’s capability to identify the most effective anticancer drugs for unseen tumor cell profiles based in on in-vitro data.

scholarly journals Mechanisms associated with the expression of cisplatin resistance in a human ovarian tumor cell line following exposure to fractionated X-irradiation in vitro

1992 ◽  
Vol 13 (7) ◽  
pp. 1209-1215 ◽  
Author(s):  
Wolfram C.M. Dempke ◽  
Sharon A. Shellard ◽  
Louise K. Hosking ◽  
Anne Marie J. Fichtinger-Schepman ◽  
Bridget T. Hill
Keyword(s):  
Tumor Cell ◽  
Cell Line ◽  
Ovarian Tumor ◽  
Cisplatin Resistance ◽  
Tumor Cell Line ◽  
Ovarian Tumor Cell ◽  
X Irradiation ◽  
Line Following
Sign in / Sign up

Export Citation Format

Share Document